Abstract Awards at the 14th Congress of ECCO
Another record number of abstracts has been submitted for the 14th Congress of ECCO. Out of 1,222 submitted scientific abstracts, 1,012 abstracts have been accepted.
Of these abstracts, 38 have been selected as Oral Presentations during the Scientific Programme and another 90 were selected as Digital Oral Presentations. ECCO Committee Members reviewed each of these presentations to select the winners of the Top 10 DOPs, IIS Abstract Awards, and the Y-ECCO Abstract Awards.
 Top 10 DOP Winners at ECCO'19, Copenhagen © ECCO |
 IIS Awardee Erwin Dreesen at ECCO'19, Copenhagen © ECCO |
Top 10 Digital Oral Presentations
DOP08 Agatha Treveil - “The regulatory landscape of intestinal cells—investigating the transcriptional effect of autophagy impairment observed in Crohn’s disease using organoid and network biology approaches”
DOP10 Archana Shubhakar - “Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease”
DOP22 Kohei Suzuki - “UC-related and segment-specific properties of patient-derived colonic organoids”
DOP36 Yael Haberman - “Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare”
DOP45 Niels Vande Casteele - “Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial”
DOP47 Laurent Peyrin-Biroulet - “Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study”
DOP56 Anne Strik - “Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial”
DOP72 Michiel de Jong - “Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia”
DOP81 Amy L. Hamilton - “Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s disease”
DOP88 Sandra Bohn Thomsen - “Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in inflammatory bowel disease patients: a nationwide Danish cohort study”
Y-ECCO Abstract Awards
OP15 Johan Burisch - “Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?”
OP29 Loris Riccardo Lopetuso - “ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer”
OP32 Robin J. Dart - “A novel mechanism of colonic epithelial-T-cell cross-talk is dysregulated in IBD”
DOP38 Bram Verstockt - “A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease”
DOP44 Iago Rodriguez-Lago - “Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU
OP18 Amit Assa - “Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial”
OP25 Erwin Dreesen - “Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease”